Recursion Pharmaceuticals (RXRX) Leases (2022 - 2025)
Historic Leases for Recursion Pharmaceuticals (RXRX) over the last 4 years, with Q3 2025 value amounting to $47.8 million.
- Recursion Pharmaceuticals' Leases fell 14.62% to $47.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.8 million, marking a year-over-year decrease of 14.62%. This contributed to the annual value of $65.9 million for FY2024, which is 9569.56% up from last year.
- Recursion Pharmaceuticals' Leases amounted to $47.8 million in Q3 2025, which was down 14.62% from $50.3 million recorded in Q2 2025.
- Recursion Pharmaceuticals' 5-year Leases high stood at $65.9 million for Q4 2024, and its period low was $33.3 million during Q4 2022.
- In the last 4 years, Recursion Pharmaceuticals' Leases had a median value of $35.1 million in 2023 and averaged $41.2 million.
- In the last 5 years, Recursion Pharmaceuticals' Leases skyrocketed by 9569.56% in 2024 and then dropped by 14.62% in 2025.
- Quarter analysis of 4 years shows Recursion Pharmaceuticals' Leases stood at $33.3 million in 2022, then rose by 1.23% to $33.7 million in 2023, then skyrocketed by 95.7% to $65.9 million in 2024, then decreased by 27.42% to $47.8 million in 2025.
- Its last three reported values are $47.8 million in Q3 2025, $50.3 million for Q2 2025, and $53.2 million during Q1 2025.